Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Site × Trastuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 20 Stomach Neoplasms 6 Neoplasms 4 Neoplasm Metastasis 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Adenocarcinoma Of Esophagus 3 Triple Negative Breast Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 HER2-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Solid Tumors 1 Resectable HER2-positive Breast Cancer 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Meningeal Neoplasms 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Gastric Cancer 1 HER2-positive Early Breast Cancer 1 Gastroesophageal Adenocarcinoma 1 Gallbladder Neoplasms 1 Endometrial Neoplasms 1

Interventions

durvalumab 3 Fulvestrant 3 Carboplatin 3 pembrolizumab 2 Pemetrexed 2 Cisplatin 2 trametinib 1 ribociclib 1 pralsetinib 1 palbociclib 1 exemestane 1 darolutamide 1 dabrafenib 1 ceralasertib 1 STX-478 1 Radiosurgery 1 Paclitaxel 1 Letrozole 1 Immunotherapy 1 Gemcitabine 1 Cetuximab 1 Anastrozole 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡